RE:RE:RE:Peak Sales of MCNA and potential. Lynch, I think you are saying that you are frustrated by the lack of published data on P3a. Therefore we have little basis for calculating market potential. You hope to get more data in the upcoming article on P3a results.
I read the last published article, this being on P2 results. It was published in the March 2009 edition of The Journal of Urology by Drs. Morales, Phadke and Steinhoff. It was 6 pages in length. It discussed mostly efficacy results and safety results. It did not discuss market size. Thereforee, I do not expect the upcoming article to help you estimate revenue potential.
However, Bioniche (and Dr. Morales for his upcoming article) should have something now that Endo did not have when they negotiated with the FDA for the P3b protocol, which was abandoned. Namely, Bioniche likely is continuing to collect data on whether/when the cancer came back for those people treated during P3a. For a slow-growing cancer like Papillary, 3-year cancer-free data is a lot more interesting than a 1-year end-point published in the press releases. This longer-term data may have helped pursuade the FDA to go with P3a data.